Skip to main content

Table 1 Metrics considered for inclusion in SCORE morbidity cohort studies

From: Protocol and baseline data for a multi-year cohort study of the effects of different mass drug treatment approaches on functional morbidities from schistosomiasis in four African countries

Recommended for study, and included in the cohort evaluation protocol:
Anthropometric measures: age-standardized height, weight, body mass index (BMI), mid-upper arm circumference (MUAC) [16,17,18]
 Blood hemoglobin [3, 13,14,15]
 Exercise tolerance measured by 20-m shuttle run (beep) test [23,24,25,26]
 Health-related quality-of-life, measured by standardized PedsQL survey instrument [27, 28]
 Ultrasonography of the abdomen and liver (S. mansoni) or of the kidneys and bladder (S. haematobium), using standardized protocols [29, 30]
Considered, but not selected for study:
Individual-level outcomes
 Indicators of the mechanism for anemia: Zinc protoporphyrin, ferritin, hepcidin, C-reactive protein, Interleukin-6 [14, 31, 32]
 Volitional activity (e.g., as measured by accelerometers, fitness trackers) [33, 34]
 Attention span [19, 35]
 School performance, school completion rates [19]
 Serologic measures of collagen metabolism [36]
 Urine abnormalities, e.g., albuminuria, hematuria [3, 37]
 Eosinophilic cationic protein (ECP) in urine [38]
Household or Population-level outcomes
 Changes in religious participation [39]
 Health system utilization [40]
 Household income, productivity, work yield [22]
 Community fertility and birth outcomes [41, 42]
 Vaccine responses in babies [43]
  1. The two sections indicate those that were selected and those that were not selected for inclusion in the final protocol
  2. Selected references for each considered outcome are cited in brackets after each listing